Cargando…

Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain

BACKGROUND AND OBJECTIVE: Ampreloxetine is a novel norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension. The objectives of this analysis were to define the pharmacokinetics of once-daily oral ampreloxetine and provide dose recommendatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanodia, Jitendra, Lo, Arthur, Baldwin, R. Michael, Graham, Richard A., Bourdet, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808980/ https://www.ncbi.nlm.nih.gov/pubmed/32856281 http://dx.doi.org/10.1007/s40262-020-00918-7

Ejemplares similares

Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
por: Lo, Arthur, et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects
por: Kanodia, Jitendra, et al.
Publicado: (2020)

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
por: Kaufmann, Horacio, et al.
Publicado: (2021)

Attention-deficit hyperactivity disorder and impulsivity in female patients with fibromyalgia
por: Yılmaz, Ertan, et al.
Publicado: (2018)

Involvement of Norepinephrine in the Control of Activity and Attentive Processes in Animal Models of Attention Deficit Hyperactivity Disorder
por: Viggiano, D., et al.
Publicado: (2004)

Attention-deficit hyperactivity disorder symptoms and quality of life in female patients with fibromyalgia
por: TÜRKOĞLU, Gözde, et al.
Publicado: (2021)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder
por: Kim, Boong-Nyun, et al.
Publicado: (2010)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
por: Kielbasa, William, et al.
Publicado: (2013)

Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder
por: Park, Subin, et al.
Publicado: (2012)

No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
por: Eslami Amirabadi, Mohammad Reza, et al.
Publicado: (2015)

Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: A True Effect or a Bias? A Systematic Review & Meta-Analysis
por: Leshem, Regina, et al.
Publicado: (2021)

Effects of Norepinephrine Reuptake Inhibition on Postural Tachycardia Syndrome
por: Green, Elizabeth A., et al.
Publicado: (2013)

Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
por: Eisenhofer, Graeme, et al.
Publicado: (2021)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Cognitive Deficits Following a Post-Myocardial Infarct in the Rat Are Blocked by the Serotonin-Norepinephrine Reuptake Inhibitor Desvenlafaxine
por: Malick, Mandy, et al.
Publicado: (2018)

Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder
por: Teuscher, Nathan S, et al.
Publicado: (2015)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

Selective Serotonin–norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy
por: Vasudev, Rahul, et al.
Publicado: (2016)

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
por: Fanelli, David, et al.
Publicado: (2021)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Norepinephrine influences the circadian clock in human dermal fibroblasts from study participants with a diagnosis of attention-deficit hyperactivity disorder
por: Palm, Denise, et al.
Publicado: (2021)

Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Huang, Jue, et al.
Publicado: (2022)

Primary School Children’s Self-Reports of Attention Deficit Hyperactivity Disorder-Related Symptoms and Their Associations With Subjective and Objective Measures of Attention Deficit Hyperactivity Disorder
por: Slobodin, Ortal, et al.
Publicado: (2022)

Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021)

Attentional Control and Subjective Executive Function in Treatment-Naive Adults with Attention Deficit Hyperactivity Disorder
por: Grane, Venke Arntsberg, et al.
Publicado: (2014)

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
por: Hopkins, Seth C., et al.
Publicado: (2015)

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2007)

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome
Publicado: (2016)

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome
por: Benavides, David R., et al.
Publicado: (2016)

Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors
por: Wen, Hui, et al.
Publicado: (2019)

The 1287 G/A polymorphism of the Norepinephrine Transporter gene (NET) is involved in Commission Errors in Korean children with Attention Deficit Hyperactivity Disorder
por: Song, Dong-Ho, et al.
Publicado: (2011)

Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adults
por: Edvinsson, Dan, et al.
Publicado: (2017)

Management of attention-deficit hyperactivity disorder
por: Verma, Rohit, et al.
Publicado: (2011)

The history of attention deficit hyperactivity disorder
por: Lange, Klaus W., et al.
Publicado: (2010)

Stigma in attention deficit hyperactivity disorder
por: Mueller, Anna K., et al.
Publicado: (2012)

Attention Deficit Hyperactivity Disorder and Athletes
por: White, Russell D., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2p29u2sdq0r7h7549hblkd76a6